Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc.FDMT · Entity 2419 | Director | June 17, 2026 | June 18, 2026 |
| Oncternal Therapeutics, Inc.ONCT · Entity 89585 | Director | June 20, 2024 | June 24, 2024 |
| Tracon Pharmaceuticals, Inc.TCON · Entity 91134 | Director · PRESIDENT AND CEO | March 12, 2024 | March 13, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
4D Molecular Therapeutics, Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.42 · Expires 2036-06-16 | Direct | 50,000 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 50,000 · Balance 50,000 F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program.
F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).
Oncternal Therapeutics, Inc.
Report date June 20, 2024 · Filed June 24, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $8.10 · Expires 2034-06-20 | Direct | 2,200 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 2,200 · Balance 2,200 F1: One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service through such vesting date.
Tracon Pharmaceuticals, Inc.
Report date March 12, 2024 · Filed March 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 406,417 |
Ending reported balance
After 2023-10-20 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-04-20 · Grant · Acquired 3,500 · Balance 402,917 F1: Shares acquired by the Reporting Person under the Issuer's 2015 Employee Stock Purchase Plan on April 20, 2023. Row 2 · 2023-10-20 · Grant · Acquired 3,500 · Balance 406,417 F2: Shares acquired by the Reporting Person under the Issuer's 2015 Employee Stock Purchase Plan on October 20, 2023. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.39 · Expires 2034-03-11 | Direct | 518,300 |
Reported balance
After 2024-03-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-12 · Grant · Acquired 518,300 · Balance 518,300 F3: 1/4th of the shares subject to this option shall vest on the first anniversary of the Grant Date shown in column 3 above. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter, on the last day of each month. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired by the Reporting Person under the Issuer's 2015 Employee Stock Purchase Plan on April 20, 2023.
F2: Shares acquired by the Reporting Person under the Issuer's 2015 Employee Stock Purchase Plan on October 20, 2023.
F3: 1/4th of the shares subject to this option shall vest on the first anniversary of the Grant Date shown in column 3 above. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter, on the last day of each month.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 18, 2026 21:41 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $9.42 | $0.00 |
DisclosureSEC source: 0001193125-26-276166 · ownership.xml · derivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-06-16 F1 · kind: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 21:35 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,333 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001193125-25-320992 · ownership.xml · derivative · entry 2 THEUER CHARLES · CIK 0001631338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,333 shares Expires 2026-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 21:35 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 9,333 | $1.14 | $10,639.62 |
DisclosureSEC source: 0001193125-25-320992 · ownership.xml · nonDerivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 17, 2025 Filed Jun 20, 2025 20:04 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $4.15 | $0.00 |
DisclosureSEC source: 0000950170-25-088487 · ownership.xml · derivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2035-06-16 F1 · kind: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2026 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2028. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 16:05 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Options · Derivative | 2,200 | $0.00 Strike: $8.10 | $0.00 |
DisclosureSEC source: 0000950170-24-076705 · ownership.xml · derivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,200 Underlying: Common Stock · 2,200 shares Expires 2034-06-20 F1 · derivative.exercise_date: One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| May 21, 2024 Filed May 23, 2024 23:16 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right To Buy) · Derivative | 22,500 | $0.00 Strike: $25.15 | $0.00 |
DisclosureSEC source: 0000950170-24-064220 · ownership.xml · derivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2034-05-20 F1 · shares: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 21, 2025 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 21, 2027. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 17:56 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | GrantEmployee Stock Option (Right to Buy) · Derivative | 518,300 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001415889-24-007846 · form4-03132024_090306.xml · derivative · entry 3 THEUER CHARLES · CIK 0001631338 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 518,300 Underlying: Common Stock · 518,300 shares Expires 2034-03-11 F3 · derivative.exercise_date: 1/4th of the shares subject to this option shall vest on the first anniversary of the Grant Date shown in column 3 above. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter, on the last day of each month. Read SEC document |
| October 20, 2023 Filed Mar 13, 2024 17:56 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | GrantCommon Stock | 3,500 | $0.13 | $466.55 |
DisclosureSEC source: 0001415889-24-007846 · form4-03132024_090306.xml · nonDerivative · entry 2 THEUER CHARLES · CIK 0001631338 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 406,417 F2 · shares: Shares acquired by the Reporting Person under the Issuer's 2015 Employee Stock Purchase Plan on October 20, 2023. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 16:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001209191-23-040285 · doc4.xml · derivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-28 F1 · derivative.exercise_date: One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| May 23, 2023 Filed May 25, 2023 23:35 UTC | 4D Molecular Therapeutics, Inc. FMDT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $17.98 | $0.00 |
DisclosureSEC source: 0001610717-23-000070 · form4.xml · derivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2033-05-22 F1 · shares: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 23, 2024 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 23, 2026. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 06:00 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 47,000 | $0.75 | $35,250.00 |
DisclosureSEC source: 0001209191-23-025930 · doc4.xml · nonDerivative · entry 2 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 399,417 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.72 to $0.7596, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 06:00 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 3,999 | $0.66 | $2,639.34 |
DisclosureSEC source: 0001209191-23-025930 · doc4.xml · nonDerivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 352,417 F1 · balance_after: Includes 3,500 shares acquired by the Reporting Person under the Issuer's 2015 Employee Stock Purchase Plan on April 20, 2023. Read SEC document |
| April 20, 2023 Filed Mar 13, 2024 17:56 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | GrantCommon Stock | 3,500 | $0.14 | $481.95 |
DisclosureSEC source: 0001415889-24-007846 · form4-03132024_090306.xml · nonDerivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 402,917 F1 · shares: Shares acquired by the Reporting Person under the Issuer's 2015 Employee Stock Purchase Plan on April 20, 2023. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 06:24 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 4,800 | $1.52 | $7,296.00 |
DisclosureSEC source: 0001209191-23-014434 · doc4.xml · nonDerivative · entry 2 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,918 Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 06:24 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 200 | $1.52 | $304.00 |
DisclosureSEC source: 0001209191-23-014434 · doc4.xml · nonDerivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,118 Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 19:55 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | GrantEmployee Stock Option (Right to Buy) · Derivative | 332,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001209191-23-007191 · doc4.xml · derivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,000 Underlying: Common Stock · 332,000 shares Expires 2033-01-31 F1 · derivative.exercise_date: 1/4th of the shares subject to this option shall vest on the first anniversary of the Grant Date shown in column 3 above. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter, on the last day of each month. Read SEC document |
| January 18, 2023 Filed Jan 19, 2023 06:05 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 6,800 | $1.62 | $11,016.00 |
DisclosureSEC source: 0001209191-23-003934 · doc4.xml · nonDerivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,918 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.6065 to $1.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| December 14, 2022 Filed Dec 15, 2022 06:00 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 23,000 | $1.29 | $29,755.10 |
DisclosureSEC source: 0001209191-22-061329 · doc4.xml · nonDerivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,118 Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 06:00 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 13,900 | $1.41 | $19,599.00 |
DisclosureSEC source: 0001209191-22-058302 · doc4.xml · nonDerivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,118 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.3992 to $1.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 06:00 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 9,200 | $1.52 | $13,984.00 |
DisclosureSEC source: 0001209191-22-055687 · doc4.xml · nonDerivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,218 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.506 to $1.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 06:00 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 6,000 | $1.59 | $9,540.00 |
DisclosureSEC source: 0001209191-22-055435 · doc4.xml · nonDerivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,018 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.5897 to $1.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. F2 · balance_after: Includes 3,500 shares acquired by the Reporting Person under the Issuer's 2015 Employee Stock Purchase Plan on October 20, 2022. Read SEC document |
| October 07, 2022 Filed Oct 11, 2022 06:00 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 5,000 | $1.77 | $8,850.00 |
DisclosureSEC source: 0001209191-22-053202 · doc4.xml · nonDerivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,518 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7601 to $1.7755, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 06:00 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 5,000 | $1.67 | $8,350.00 |
DisclosureSEC source: 0001209191-22-052605 · doc4.xml · nonDerivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,518 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.6650 to $1.6855, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| September 22, 2022 Filed Sep 26, 2022 06:00 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 5,000 | $1.76 | $8,800.00 |
DisclosureSEC source: 0001209191-22-051200 · doc4.xml · nonDerivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,518 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.735 to $1.7899, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| July 22, 2022 Filed Jul 25, 2022 06:00 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 4,500 | $1.85 | $8,325.00 |
DisclosureSEC source: 0001209191-22-043061 · doc4.xml · nonDerivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,518 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.835 to $1.8499, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| July 13, 2022 Filed Jul 14, 2022 06:00 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 3,000 | $1.84 | $5,520.00 |
DisclosureSEC source: 0001209191-22-042093 · doc4.xml · nonDerivative · entry 2 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,018 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.83 to $1.8426, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| July 12, 2022 Filed Jul 14, 2022 06:00 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 3,000 | $1.87 | $5,610.00 |
DisclosureSEC source: 0001209191-22-042093 · doc4.xml · nonDerivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,018 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.86 to $1.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 18:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001209191-22-038030 · doc4.xml · derivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-16 F1 · derivative.exercise_date: One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| May 23, 2022 Filed May 25, 2022 23:06 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001567619-22-011722 · doc1.xml · derivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2032-05-22 F1 · shares: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 23, 2023 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 23, 2025. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document |
| May 09, 2022 Filed May 11, 2022 06:00 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 10,000 | $1.85 | $18,500.00 |
DisclosureSEC source: 0001209191-22-028188 · doc4.xml · nonDerivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,018 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.80 to $1.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| May 06, 2022 Filed May 10, 2022 06:00 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 2,500 | $1.97 | $4,925.00 |
DisclosureSEC source: 0001209191-22-027975 · doc4.xml · nonDerivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,018 Read SEC document |
| April 29, 2022 Filed May 3, 2022 06:00 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 5,000 | $1.97 | $9,854.50 |
DisclosureSEC source: 0001209191-22-026562 · doc4.xml · nonDerivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,518 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.9717 to $1.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| April 21, 2022 Filed Apr 25, 2022 06:00 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 4,500 | $2.30 | $10,350.00 |
DisclosureSEC source: 0001209191-22-025471 · doc4.xml · nonDerivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,518 F1 · balance_after: Includes 3,500 shares acquired by the Reporting Person under the Issuer's 2015 Employee Stock Purchase Plan on April 20, 2022. Read SEC document |
| April 08, 2022 Filed Apr 12, 2022 06:00 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 2,000 | $2.50 | $5,000.00 |
DisclosureSEC source: 0001209191-22-024070 · doc4.xml · nonDerivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,518 Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 06:05 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 4,000 | $2.70 | $10,800.00 |
DisclosureSEC source: 0001209191-22-021876 · doc4.xml · nonDerivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,518 Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 06:00 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 1,200 | $2.45 | $2,940.00 |
DisclosureSEC source: 0001209191-22-020678 · doc4.xml · nonDerivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,518 Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 17:00 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | GrantEmployee Stock Option (Right to Buy) · Derivative | 265,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001209191-22-005939 · doc4.xml · derivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,000 Underlying: Common Stock · 265,000 shares Expires 2032-01-27 F1 · derivative.exercise_date: 1/4th of the shares subject to this option shall vest on the first anniversary of the Grant Date shown in column 3 above. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter, on the last day of each month. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 16:21 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 3,500 | $2.82 | $9,870.00 |
DisclosureSEC source: 0001209191-21-066096 · doc4.xml · nonDerivative · entry 2 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,318 Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 16:21 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 681 | $2.88 | $1,961.28 |
DisclosureSEC source: 0001209191-21-066096 · doc4.xml · nonDerivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,818 Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 07:00 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 3,000 | $3.42 | $10,245.00 |
DisclosureSEC source: 0001209191-21-063520 · doc4.xml · nonDerivative · entry 2 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,137 Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 07:00 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 1,000 | $3.41 | $3,410.00 |
DisclosureSEC source: 0001209191-21-063520 · doc4.xml · nonDerivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,137 F1 · balance_after: Includes 3,405 shares acquired by the Reporting Person under the Issuer's 2015 Employee Stock Purchase Plan on October 20, 2021. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 06:05 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 3,000 | $3.56 | $10,680.00 |
DisclosureSEC source: 0001209191-21-052132 · doc4.xml · nonDerivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,732 F1 · balance_after: Includes 3500 shares acquired by the Reporting Person under the Issuer's 2015 Employee Stock Purchase Plan on April 20, 2021. Read SEC document |
| May 25, 2021 Filed May 27, 2021 18:06 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $5.14 | $0.00 |
DisclosureSEC source: 0001209191-21-036318 · doc4.xml · derivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-05-25 F1 · derivative.exercise_date: One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| May 17, 2021 Filed May 20, 2021 00:36 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $26.89 | $0.00 |
DisclosureSEC source: 0001567619-21-010751 · doc1.xml · derivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2031-05-16 F1 · shares: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 17, 2022 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 17, 2024. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 18:00 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | GrantEmployee Stock Option (Right to Buy) · Derivative | 180,000 | $0.00 Strike: $9.14 | $0.00 |
DisclosureSEC source: 0001209191-21-006882 · doc4.xml · derivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2031-01-28 F1 · derivative.exercise_date: 1/4th of the shares subject to this option shall vest on the first anniversary of the Grant Date shown in column 3 above. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter, on the last day of each month. Read SEC document |
| January 27, 2021 Filed Jan 28, 2021 06:00 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 11,000 | $8.98 | $98,771.20 |
DisclosureSEC source: 0001209191-21-005826 · doc4.xml · nonDerivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,232 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.93 to $9.079, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 06:00 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 1,000 | $9.98 | $9,980.00 |
DisclosureSEC source: 0001209191-20-065423 · doc4.xml · nonDerivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,232 Read SEC document |
| October 21, 2020 Filed Oct 23, 2020 06:00 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 2,000 | $4.38 | $8,769.00 |
DisclosureSEC source: 0001209191-20-055634 · doc4.xml · nonDerivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,232 F1 · balance_after: Includes 350 shares acquired by the reporting person under the Issuer's 2015 Employee Stock Purchase Plan on October 20, 2020. Read SEC document |
| September 23, 2020 Filed Sep 25, 2020 06:00 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 107 | $4.72 | $505.05 |
DisclosureSEC source: 0001209191-20-052046 · doc4.xml · nonDerivative · entry 2 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,882 Read SEC document |
| September 23, 2020 Filed Sep 25, 2020 06:00 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 4,893 | $4.72 | $23,093.98 |
DisclosureSEC source: 0001209191-20-052046 · doc4.xml · nonDerivative · entry 1 THEUER CHARLES · CIK 0001631338 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,775 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.